Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 7.50 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo Inc., Gilead Sciences Inc., Incyte Corporation, Kite Pharma, Inc., Novartis Pharmaceuticals Corporation, Oncopeptides, Pfizer, and Sanofi Genzyme.
5th Annual Live Medical Crossfire®: Hematologic Malignancies
Release Date: August 30, 2021
Expiration Date: August 30, 2022
Activity Overview
Current standards of practice for treating hematologic malignancies are continually evolving as new clinical trial data emerge. Physicians who treat a broad range of patients with hematologic malignancies—leukemia, lymphoma, multiple myeloma, and myelodysplastic/myeloproliferative neoplasms—need to stay informed about changing treatment paradigms across multiple lines of care to confidently personalize clinical decisions for their patients. As such, comprehensive, case-based discussions that provide real-world clinical perspectives can help shape modern management of hematologic malignancies today.
This online Medical Crossfire®: Hematologic Malignancies program provides presentations from the 5th Annual Live Medical Crossfire®: Hematologic Malignancies Virtual Webcast held on July 17, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician, as it focuses on the practical aspects of managing patients with hematologic malignancies. The program is designed both to disseminate important information to health professionals who did not attend the live meeting and to help reinforce learnings for those who did.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo Inc., Gilead Sciences Inc., Incyte Corporation, Kite Pharma, Inc., Novartis Pharmaceuticals Corporation, Oncopeptides, Pfizer, and Sanofi Genzyme
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational activity is directed toward hematologic and medical oncologists involved in the treatment and management of patients with leukemia, lymphoma, multiple myeloma, and other hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze testing strategies that may inform clinical decision-making in the management of hematologic malignancies
- Apply clinical trial results to multiple lines of care when managing hematologic malignancies
- Implement optimal strategies to treat hematologic malignancies
- Assess disparities in the care of patients with hematologic malignancies
- Develop strategies to prevent, minimize, and manage treatment-related toxicities in patients with leukemia, lymphoma, and multiple myeloma
- Discuss key emerging data sets regarding the management of patients with hematologic malignancies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Co-Chairs
Kraft Family Professor of Medicine
Harvard Medical School
Program Director, Jerome Lipper Multiple Myeloma Center
LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant: Pfizer; Amgen; AstraZeneca; Janssen Pharmaceutical; Precision Biosciences; MANA PHARMA, SL; WindMIL Therapeutics; Stock Shareholder: OncoPep, Inc, C4 Therapeutics; Raqia Therapeutics; NextRNA Therapeutics.
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: Amgen, Pfizer, Takeda Pharmaceutical, Adaptive Biotechnologies, Novartis Pharmaceuticals, Spectrum Pharmaceuticals, AbbVie, Bristol Myers Squibb.
Chief, Lymphoma Service
Division of Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, BeiGene, Bristol Myers Squibb/Celgene, Epizyme, Genentech/Roche, Gilead/Kite Pharma, Genmab A/S, Janssen Pharmaceuticals, Incyte, Miltenyi Biotec, MorphoSys AG, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, VelosBio.
Faculty
Professor of Medicine, Hematology and Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Clinical and Translational Sciences Institute
Chicago, IL
Disclosures: Grant Research Support: AbbVie, ALX Oncology, Amgen, Aprea Therapeutics, Astellas Pharma, BioSight Ltd, Bristol Myers Squibb, Boehringer Ingelheim, FUJIFILM Pharmaceuticals USA, Immunogen, Kartos Therapeutics, Kura Oncology; Consultant: AbbVie, Astellas Pharma, BioSight Ltd (not paid), Kura Oncology; Speakers’ Bureau: Astellas Pharma; Other: GlycoMimetics–Data and Safety Monitoring Committee.
Professor of Medicine
Mayo Clinic College of Medicine
Chair, Lymphoma Group
Division of Hematology
Co-Leader, Hematologic Malignancies Program
Mayo Clinic Cancer Center
Rochester, MN
Disclosures: Grant Research Support: Bristol Myers Squibb, Takeda Oncology, Seagen, Inc., ADC Therapeutics, Affimed, GmbH; Regeneron Pharmaceuticals, Trillium Therapeutics.
Chief, Division of Lymphoma
Harold and Virginia Lash Endowed Chair in
Lymphoma Research
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Grant Research Support: Merck & Co, Bristol Myers Squibb, Affimed, Adaptive Biotechnologies, Roche Pharmaceuticals, Tensha Therapeutics, Otsuka America Pharmaceutical, Leadient Biosciences, Genentech, IGM Biosciences, Kite Pharma; Consultant: Merck & Co, Bristol Myers Squibb, Pfizer, Affimed GmbH, Adaptive Biotechnologies, Infinity Pharmaceuticals, ADC Therapeutics, Celgene, MorphoSys US, Daiichi Sankyo, Miltenyi Biotec, Tessa Therapeutic, GenMab A/S, C4 Therapeutics, Enterome SA, Regeneron Pharmaceuticals, Epizyme.
Hematologic Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Ellin Berman has no relevant financial relationships with ineligible companies.
Director, Leukemia Program
Vice Chair, Strategy and Enterprise Development
Taussig Cancer Institute
Cleveland Clinic
Associate Professor
Department of Medicine
Lerner College of Medicine
Cleveland, OH
Disclosures: Grant Research Support: Celgene; Consultant: Celgene, Agios Pharmaceuticals, Shire plc, Novartis Pharmaceuticals, Jazz Pharmaceuticals; Speakers’ Bureau: Celgene, Agios Pharmaceuticals, Shire plc, Novartis Pharmaceuticals, Jazz Pharmaceuticals; Other: Independent Review Committee (AbbVie, Takeda Oncology, Syndax Pharmaceuticals).
Associate Professor, Division of Hematology
University of Washington School of Medicine
Assistant Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Disclosures: Grant Research Support: Amgen, Kite Pharma/Gilead, Merck & Co, Pfizer, Vanda Pharmaceuticals; Consultant: Amgen, Kite Pharma/Gilead; Stock Shareholder: Seagen.
Professor of Medicine (Hematology and Medical Oncology)
Icahn School of Medicine at Mount Sinai
Director of Clinical Research, Multiple Myeloma Program
Associate Director of Clinical Research, Mount Sinai Cancer Clinical Trials Office
Mount Sinai Hospital
New York, NY
Disclosures: Grant Research Support: Janssen Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Amgen, Pharmacyclics LLC, Seagen Inc., Takeda Oncology; Consultant: Janssen Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Sanofi Genzyme, Seagen, Inc, Oncopeptides, Takeda Oncology, Antengene, GlaxoSmithKline, Secura Bio, Shattuck Labs.
Director, Georgia Cancer Center
Cecil F. Whitaker Jr GRA Eminent Scholar Chair in Cancer
Augusta University
Augusta, GA
Disclosures: Grant Research Support: Takeda Oncology, Bristol Myers Squibb, Pfizer, Novartis Pharmaceuticals, Sun Pharmaceutical Industries; Consultant: Takeda Oncology, Bristol Myers Squibb, Novartis Pharmaceuticals, Pfizer.
Professor of Medicine (Hematology)
Director, Hematology Clinic
Vice Chair, Leukemia Committee
Southwest Oncology Group
Stanford University School of Medicine
Stanford, CA
Disclosures: Grant Research Support: AbbVie, Acerta Pharma, BeiGene, Gilead Sciences, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Pharmacyclics LLC; Consultant: AbbVie, BeiGene, Janssen Pharmaceuticals, Genentech, Pharmacyclics LLC.
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: Bristol Myers Squibb; Pfizer; Astellas Pharma; AbbVie; Genentech; NovImmune; Immunogen; Forty Seven, Inc; Incyte; Daiichi Sankyo; Roche Pharma; Consultant: Otsuka Pharmaceutical; Pfizer; Incyte; Immunogen; Bristol Myers Squibb; AbbVie; Genentech; Roche Pharma; Novartis Pharmaceuticals; Astellas Pharma; Daiichi Sankyo; Jazz Pharmaceuticals; Forty Seven, Inc; Trillium Therapeutics; Gilead Sciences.
Professor, Department of Medicine
New York University Grossman School of Medicine
Director, Clinical Myeloma Program
Perlmutter Cancer Center
New York University Langone Health
New York, NY
Disclosures: Grant Research Support: Celgene; Consultant: Adaptive Biotechnologies, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, Roche, Sanofi Genzyme, Takeda Oncology.
Professor and Associate Medical Director, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: AstraZeneca, BeiGene; Other: Advisory Boards: Janssen Pharmaceuticals, AstraZeneca, BeiGene.
Professor, Department of Lymphoma-Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: Roche Pharma, Celgene, AbbVie, TG Therapeutics; Janssen Pharmaceuticals.
Professor, Chief, and Deputy Chair of Translational Research; Department of Leukemia
Division of Cancer Medicine
Chair, Faculty Senate
Chief, Section of Myelodysplastic Syndromes
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: Bristol Myers Squibb, Astex Pharmaceuticals, Novartis Pharmaceuticals, AbbVie, Genentech, Applied Pharma Research SA, Curis, Gilead Sciences.
Senior Member and Section Head, Leukemia and MDS Section
Vice Chair, Department of Malignant Hematology
H Lee Moffitt Cancer Center and Research Institute
Professor, Medicine and Oncologic Sciences
University of South Florida
Tampa, FL
Disclosures: Consultant: AbbVie, Agios Pharmaceuticals Inc, Bristol Myers Squibb/Celgene, Geron, Jazz Pharmaceuticals, Novartis Pharmaceuticals; Speakers’ Bureau: AbbVie, Agios Pharmaceuticals, Bristol Myers Squibb, Jazz Pharmaceuticals.
Professor, Clinical Medicine
Columbia University
Director, Multiple Myeloma and Amyloidosis Program
College of Physicians and Surgeons
NewYork-Presbyterian Hospital/Columbia University Medical Center
New York, NY
Disclosures: Grant Research Support: Sanofi Genzyme, Karyopharm Therapeutics; Consultant: Janssen Pharmaceuticals, AbbVie, Amgen, Sorrento Therapeutics, Sanofi Genzyme, Caelum Biosciences; Stock Shareholder: Caelum Biosciences; Other: Board of Directors–Caelum Biosciences
Senior Associate Dean, Innovation and Initiatives
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine
Attending Physician
NewYork-Presbyterian Hospital
New York, NY
Disclosures: Consultant: Sutro Biopharma, Miltenyi Biotec, AstraZeneca, Epizyme, Bristol Myers Squibb/Celgene, Regeneron Pharmaceuticals, Bayer Pharmaceuticals, Gilead/Kite Pharma, Karyopharm Therapeutics, GenMab A/S, Genentech/Roche, AbbVie, Incyte, Janssen Pharmaceuticals.
Professor, Division of Hematology Oncology
Department of Medicine
Hospital of the University of Pennsylvania
Perelman Center of Advanced Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures: Grant Research Support: BioSight, Celgene, Roche Pharma, Kura Oncology, Onconova Therapeutics; Other: Honorarium: Acceleron Pharma, Agios Pharmaceuticals, Daiichi Sankyo, Bristol Myers Squibb, Jazz Pharmaceuticals.
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, AbbVie, Acerta Pharma/AstraZeneca, Sunesis Pharmaceuticals, Loxo Oncology, Regeneron Pharmaceuticals; Consultant: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, AbbVie, Acerta Pharma, Sunesis Pharmaceuticals, Loxo Oncology, Regeneron Pharmaceuticals, Johnson & Johnson, Celgene; Other: Advisory Board: Data and Safety Monitoring Board: TG Therapeutics, Celgene.
Assistant Professor, Department of Pediatrics
Perelman School of Medicine at the University of Pennsylvania
Fellowship Director, Cancer Immunotherapy
Children’s Hospital of Philadelphia
University of Pennsylvania School of Medicine
Philadelphia, PA
Disclosures: Grant Research Support: Clinical Trial Support: Novartis Pharmaceuticals; Consultant: Novartis Pharmaceuticals.
Assistant Professor of Medicine
Blood and Marrow Transplantation and Cellular Therapy
Stanford University Medical Center
Stanford, CA
Disclosures: Grant Research Support: Jasper Therapeutics, Adaptive Biotechnologies, Astellas Pharma, Kite Pharma, Baxalta; Consultant: Amgen, Pfizer, Jazz Pharmaceuticals; Shareholder: Corvus Pharmaceuticals.
Section Chief, New Drug Development
Director, Lymphoma Outcomes Database
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: Bristol Myers Squibb/Celgene Corporation, Epizyme, Genentech, Janssen Pharmaceuticals, Merck & Co, Novartis Pharmaceuticals, TG Therapeutics, Takeda Oncology; Consultant: ADC Therapeutics, Bayer Pharmaceutical, Bristol Myers Squibb/Celgene, Genentech, Kite Pharma, Janssen Pharmaceuticals, MorphoSys AG, Novartis Pharmaceuticals, TG Therapeutic,; Takeda Oncology.
Consultant, Division of Hematology
Department of Internal Medicine
Professor of Medicine and Oncology
Mayo Clinic
Rochester, MN
Disclosures: Grant Research Support: MorphoSys, Celgene/Bristol Myers Squibb, Roche/Genentech, NanoString Technologies; Consultant: MorphoSys, Celgene/Bristol Myers Squibb, Roche/Genentech, Kite, Ryvu Therapeutics.
Medical Oncologist, Hematologic Division
Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: Pharmacyclics/AbbVie, Rafael Pharmaceuticals; Consultant: Janssen Pharmaceuticals, MorphoSys AG, Epizyme.
Associate Director for Clinical Science
Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for Clinical Trials and Research
Professor, Division of Hematology/Oncology
School of Medicine
University of California Irvine
Irvine, CA
Disclosures: Grant Research Support: Acerta Pharma, TG Therapeutics, Regeneron Pharmaceuticals, Gilead Sciences, Pharmacyclics, ProNAi Therapeutics; Consultant: Amgen, Celgene, GlaxoSmithKline, Janssen Pharmaceuticals.
Professor
University of Washington School of Medicine
Professor, Clinical Research Division
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Research Center
Seattle, WA
Disclosures: Grant Research Support: Novartis Pharmaceuticals; Consultant: Novartis Pharmaceuticals, Amgen, Takeda Oncology, Cepheid, Bristol Myers Squibb, Genentech.
Professor, Department of Medicine
Harvard Medical School
Director, Multiple Myeloma Program
Medical Oncology
Massachusetts General Hospital
Boston, MA
Disclosures: Grant Research Support: bluebird bio; Consultant: Celgene, Takeda Oncology, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Immuneel Therapeutics, Caribou Biosciences.
Director, Lymphoma Program
Lymphoma Translational Research
Robert and Margarita Louis-Dreyfus Professor
Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research
Abramson Cancer Center at Pennsylvania Hospital
University of Pennsylvania
Philadelphia, PA
Disclosures: Grant Research Support: AbbVie, Acerta Pharma, Celgene, Genentech/Roche, Juno Therapeutics, Merck & Co, Novartis Pharmaceuticals; Consultant: Acerta Pharma, Allogene Therapeutics, AstraZeneca, BeiGene, Celgene, Genentech/Roche, Incyte, Juno Therapeutics, Loxo Oncology, Nordic Nanovector, Novartis Pharmaceuticals, Tessa Therapeutics.
Anjuli Seth Nayak Professor in Leukemia
Director, Leukemia Program
Section of Hematology and Oncology
The University of Chicago
Chicago, IL
Disclosures: Consultant: Servier, Laboratories, AbbVie, Amgen, Pfizer, Agios Pharmaceuticals, Kite Pharma, Kura Oncology, MorphoSys AG, GlaxoSmithKline. Daiichi Sankyo.
Assistant Member, Department of Malignant Hematology
H Lee Moffitt Cancer Center and Research Institute
Assistant Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL
Disclosures: Consultant: Astellas Pharma, Bristol Myers Squibb, Novartis Pharmaceuticals, Gilead Sciences, AROG Pharmaceuticals.
United Energy Resources, Inc, Professor of Medicine
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Chief, Section for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: Incyte, Roche, NS Pharma, Celgene, Gilead Sciences, Promedior, CTI BioPharma, AbbVie, Blueprint Medicines, Novartis Pharmaceuticals, Sierra Oncology, PharmaEssentia, Constellation Pharmaceuticals, Italfarmaco, Protagonist Therapeutics, Kartos Therapeutics.
Director, Lymphoma Drug Development
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Baltimore, MD
Chief, Leukemia Service
Medical Director, Infusion Services
Professor, Department of Oncology
Roswell Park Comprehensive Cancer Institute
Buffalo, NY
Disclosures: Consultant: Amgen, Astellas Pharma, AbbVie, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Jazz Pharmaceuticals, Kite Pharma, Novartis Pharmaceuticals, Pfizer, Stemline Therapeutics, Takeda Oncology; Speakers’ Bureau: Stemline Therapeutics, DAVA Oncology, Kura Oncology.
DB Lane Cancer Research Distinguished Professor
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director, Department of Leukemia
Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: GlaxoSmithKline, Novartis Pharmaceuticals, AbbVie, Genentech, Karyopharm Therapeutics, Pharmacyclics Ascerta Pharma Gilead Sciences, Juno Therapeutics, Kite Pharma, Sunesis, miRagen Therapeutics, Consultant: Sanofi Genzyme.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
